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ABSTRACT
There are no studies evaluating the glucose variability in different periods of Ramadan fasting
in patients with type 2 diabetes using continuous glucose monitoring (CGM). This study
examined the effect of Ramadan fasting on interstitial glucose (IG) variability in early,- late-,
and post-Ramadan compared to pre-Ramadan days in non-insulin-treated type 2 diabetes
patients. Participants had a CGM system connected 2 or 3 days before Ramadan start, which
was removed on the third or fourth day of Ramadan. CGM performance continued for a total
of 6 days. A second CGM performance started on the 27th or 28th day of Ramadan and ended
on the 4th or 5th post-Ramadan day. First, CGM recordings were divided into pre-Ramadan
and early-Ramadan CGM, and second recordings into late-Ramadan and post-Ramadan. At
each visit, blood pressure, body weight, and waist circumference were measured, and fasting
blood samples were collected for HbA1c and plasma glucose. All patients received recom-
mended Ramadan education before Ramadan. Thirty-three patients (mean age
55.0 ± 9.8 years, 73% males) were prospectively included. IG variability, estimated as mean
amplitude of glycaemic excursions (MAGE), increased significantly in early-Ramadan com-
pared to pre-Ramadan (P = 0.006) but not in late-Ramadan and post-Ramadan recording days.
Only patients on >2 anti-diabetic drugs (n = 16, P = 0.019) and those on sulphonylureas
(n = 14, P = 0.003) showed significant increase in MAGE in early-Ramadan. No significant
changes were seen in coefficient of variation, time in range, time in hyperglycaemia, or time in
hypoglycaemia. Except for an initial increase in glucose variability, fasting Ramadan for
patients with non-insulin-treated type 2 diabetes did not cause any significant changes in
glucose variability or time in hypoglycaemia during CGM recording days compared to non-
fasting pre-Ramadan period.
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1. Introduction
Ramadan fasting for Muslims is refraining from
food and fluid intake from dawn to sunset for a
month every lunar calendar year. For patients with
diabetes, this implies major changes in their daily
routines, including mealtimes, medication fre-
quency and doses, and daily activities.
Consequently, there is an increased risk of affect-
ing metabolic control for a whole month annually.
There is little information regarding how plasma
glucose values and its fluctuation are affected during
Ramadan fasting in adult patients with type 2 dia-
betes. Most studies done using continuous glucose
monitoring (CGM) during Ramadan fasting included
adolescent patients with type 1 diabetes [1–4]. In
these studies, no significant difference in glucose
fluctuation could be shown during Ramadan fasting
compared to non-fasting periods. However, mean
amplitude of glycaemic excursion (MAGE), a measure
of glycaemic variability, was not used in these studies.
In one study, that included patients with both type 1
and type 2 diabetes, a different pattern of excursions
could be seen but no significant difference in glucose
variability was measured. However, amplitude of
excursions was greater among insulin- or sulphony-
lurea (SU)-treated patients [5]. Hypoglycaemia during
Ramadan fasting has been a matter of concern. In one
study using CGM in patients with diabetes on insulin
pump treatment, no difference in hypoglycaemic epi-
sodes could be seen during daytime and night-time
[4]. Kaplan et al. on the other hand reported signifi-
cantly higher rates of hypoglycaemia during daytime
compared to night-time [2].
Until now, no studies on diabetes patients have
assessed glucose variability in different periods of
Ramadan fasting using CGM. The main objective of
this study was to examine the effect of Ramadan
fasting on interstitial glucose (IG) variability in early-,
late-, and post-Ramadan compared to pre-Ramadan
days in non-insulin-treated type 2 diabetes patients
using CGM.
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2. Material and methods
2.1. Study population and design
Thirty-three patients with non-insulin-treated type 2
diabetes mellitus followed at a tertiary diabetes centre
(Rashid Centre for Diabetes and Research, Ajman,
UAE) were included in this clinical observational
study. Patients were included prospectively at the
diabetic clinics according to inclusion criteria during
planned control visits to their diabetes team starting
6 months before Ramadan start. All patients were
Emirati national citizens. Inclusion criteria were type
2 diabetes mellitus, age ≥ 18 years, males and
females, and having the intention to fast during the
Ramadan month in 2017 (the first day of Ramadan
was 26 May and the last day was 24 June). Overall
exclusion criteria were insulin treatment, known liver
insufficiency, defined as an elevation of serum alanine
aminotransferase (ALAT) or aspartate aminotransfer-
ase (ASAT) levels twice higher than the normal super-
ior limit or spontaneous international normalized ratio
> 1.1, severe renal insufficiency, defined as estimated
glomerular filtration rate < 30 mL/min/1.73 m2, can-
not or do not intend to fast during Ramadan,
untreated metabolic or endocrine diseases (e.g. pheo-
chromocytoma, Cushing syndrome, or acromegaly), or
on corticosteroid treatment. The study was approved
by the regional ethics committee in Ajman Medical
District, Ministry of Health and Prevention. Written
consent was given by all subjects before beginning
the study.
2.2. CGM performance and data collection
The Medtronic iPro®2 CGM system was used to perform
CGM. IG was measured every 5 min. All subjects had the
CGM system connected, after education about the sys-
tem and calibration, for a first recording of IG values 2 or
3 days before Ramadan started (visit 1). The CGM device
was removed on the third or fourth day of Ramadan
(visit 2). The CGM performance continued for total of
6 days on each subject. During both visits, blood pres-
sure, height, and body weight were measured, and fast-
ing venous blood samples for HbA1c (measured in
derived NGSP units, % to one decimal point), plasma
glucose, and serum creatinine were taken after a 10-h
fast. All samples consisted of whole blood drained into 6-
mL serum separation tubes, plasma separation tubes, and
BDMicrotainer tubes with EDTA (BD Biosciences, Franklin
Lakes, NJ, USA). Blood chemistries were analysed the
same morning during the study. Blood pressure was
measured in the supine position after a 5-min rest with
the arm at the level of the heart. Height was measured to
the nearest centimetre, weight to the nearest kilogram in
subjects wearing light clothes, but not shoes, and BMI
was calculated. Patients’ data including diabetes dura-
tion, medications, and reported episodes of hypoglycae-
mia were registered during study time. The second CGM
performance started on the 27th or 28th day of Ramadan
(visit 3) and ended on the 4th or 5th post-Ramadan day
(visit 4). The first 6 days of recordings were considered. All
body measurements, blood samples, and data collection
done at visits 1 and 2 were repeated at visits 3 and 4. The
first CGM recordings were divided into two periods: pre-
Ramadan (days before Ramadan start) and early-
Ramadan CGM, and the second recordings were divided
into late-Ramadan (last days of Ramadan) and post-
Ramadan (Figure 1). At least a whole day reading was
considered in analysis in each period.
Software KADIS®DCC (version 0.4.6.1, 2017,
Institute of Diabetes, Karlsburg, Germany) was used
to calculate sensor-derived mean and standard devia-
tion (SD) of IG, and as MAGE for pre-, early-, late-, and
post-Ramadan CGM recordings separately. Coefficient
of variation was calculated from mean and SD of IG.
Time in range (per cent of IG readings 70–180 mg/dl),
time in hypoglycaemia (per cent of IG readings
< 70 mg/dl), and time in hyperglycaemia (per cent
of IG readings > 180 mg/dl) were calculated [6].
Subjects were asked to report any symptomatic or
serious hypoglycaemic events defined as hypoglycae-
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Figure 1. Time plan for the study.
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requiring external assistance for recovery [7] during
CGM recording days or fast breaking during Ramadan
month. Education and advice about adjustment of
anti-diabetic treatment and doses for the Ramadan
period were given to all subjects before Ramadan
started according to clinical guidelines [8].
2.3. Statistical analysis
Values are given as mean ± SD or median ± range.
Normality assumption was tested using Shapiro–Wilk
test. Comparisons between groups were made using
the Mann–Whitney test. Statistical significance was
defined as a P-value < .05. Statistical analysis was
performed using SPSS statistics version 25 (IBM cor-
poration, Armonk, NY, USA).
3. Results
3.1. General characteristics
Thirty-three patients were included in this study, of
whom 73% were men. One patient dropped out in
the second CGM recording, and thus only this
patient’s pre-Ramadan and early-Ramadan readings
were included. Average recording days of each period
were 2.3 days. The mean age was 55 ± 9.8 years, and
the mean diabetes duration 10.4 ± 6.8 years. At the
first visit (Table 1), mean HbA1c was 6.7 ± 1.0%, and
mean fasting plasma glucose was 133.5 ± 35.5 mg/dl.
The average fasting time was 15 h and 8 min
each day.
In accordance with the inclusion criteria, none of
the patients had insulin treatment during the study
time. Five patients were on anti-diabetic monother-
apy (4 patients on metformin and 1 on SU), 12
patients had two anti-diabetic medications, and 16
patients had three or more anti-diabetic medications.
At the start of the study, 32 patients had metformin as
part of their treatment, 14 patients had SU, 21
patients had dipeptidyl peptidase 4 (DPP-4) inhibitor,
4 patients had glucagon-like peptide-1 receptor (GLP-
1) agonist, 3 patients had pioglitazone, and 6 patients
had sodium-glucose co-transporter-2 (SGLT2) inhibi-
tor. During the follow-up, one patient was started on
DPP-4 inhibitor instead of pioglitazone, which was
stopped, and another patient had SGLT-2 inhibitor
added to treatment. No other medication changes
were made before the end of the study.
One patient had symptomatic hypoglycaemia dur-
ing the early-Ramadan period. The patient was on
metformin treatment only. No serious hypoglycaemic
episodes were reported by the patients during
Ramadan fasting, and none of the patients broke
his/her Ramadan fasting.
3.2. Glucose variability
MAGE showed significant increase at early-Ramadan
fasting days compared to pre-Ramadan days (70.0
[55.5–88.5] vs. 54.0 [42.5–89.5], P = 0.007), while no
statistically significant changes were seen in late-
Ramadan fasting days or post-Ramadan days com-
pared to pre-Ramadan. Subgroup analyses showed
significant increase in MAGE at early-Ramadan fasting
days among male patients (P = 0.008), patients on >2
anti-diabetic medications (P = 0.027), and patients
treated with SU (P = 0.009). However, no significant
changes in MAGE at late-Ramadan or post-Ramadan
periods were seen in these subgroups (Table 2). Male
patients (26.0 [18.0–33.0] vs. 29.0 [21.0–38.0],
P = 0.038), and patients on SU treatment (32.0 [20.0–
40.5] vs. 34.0 [25.0–46.0], P = 0.034), showed increased
SD at early-Ramadan fasting days compared to pre-
Ramadan days. No significant changes in SD were
seen at late-Ramadan or post-Ramadan periods in
these subgroups.
Time in range (70–180 mg/dl), time in hyperglycae-
mia (>180 mg/dl), time in hypoglycaemia (<70mg/dl),
CV, and mean IG showed no statistical significant
changes during the four CGM study periods.
4. Discussion
In this study including non-insulin-treated patients
with type 2 diabetes, fasting during Ramadan month
resulted in an initial increased glucose variability mea-
sured by MAGE, which returned to pre-Ramadan
levels in the late-and post-Ramadan period. Male
patients and patients treated with SU showed an
initial increase in both MAGE and SD. No significant
differences were seen in the percentage of euglyce-
mic, hypoglycaemic or hyperglycaemic values during
early- and late-Ramadan compared to pre- and post-
Ramadan. Glycaemic control measured by HbA1c
showed no significant changes after Ramadan com-
pared to pre-fasting period.
To our knowledge, there are no previous studies
examining glucose variability using CGM during
Ramadan fasting in patients with type 2 diabetes
without insulin treatment. In one study including
patients with both type 1 and type 2 diabetes as
well as healthy subjects, no significant changes were
seen in glucose variability measured as MAGE and
Table 1. Clinical patient characteristics.
Male (%) 73.0
Age (years) 55.0 (9.8)
Diabetes duration (years) 10.4 (6.8)
Weight (kg) 84.9 (17.3)
BMI (kg/m2) 30.6 (6.0)
FPG (mg/dl) 133.5 (35.5)
HbA1c (%) 6.7 (1.0)
Data are shown in mean (SD). FPG = fasting plasma glucose, BMI = body
mass index, HbA1c = glycosylated haemoglobin A1c.
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mean IG, and no difference was seen in rate of hypo-
glycaemia [5].
Studying glucose variability using CGM in adoles-
cent patients with type 1 diabetes, Kaplan et al. could
not show any significant changes in mean IG between
Ramadan fasting and non-Ramadan periods [3]. Afandi
et al. also used CGM to compare well and poorly con-
trolled adolescent patients with type 1 diabetes during
Ramadan fasting. Both glucose variability, measured as
mean IG and SD, percentage of hypoglycaemia and
hyperglycaemia were higher in the poorly controlled
group [1]. However, unlike the present study, they
included younger patients with type 1 diabetes and
compared two different groups of patients rather than
following glucose fluctuations for the same patient
during different periods of Ramadan.
In our study, patients on SU and patients on more
than two anti-diabetic drugs showed early significant
increase in MAGE. SU has previously been associated
with higher risk of hypoglycaemia during Ramadan
fasting compared to other oral anti-diabetic drugs in
patients with diabetes type 2 [9–15]. It is worth men-
tioning that no CGM was used in these studies to
monitor glycaemic variation and hypoglycaemia.
However, in contrast to these observational studies,
SU (including gliclazide) has not been associated with
higher rates of hypoglycaemia compared to DPP-4
inhibitors in other studies [16,17]. This is probably
due to individualized patient education and advice
about dose adjustments used in these studies.
In our study, no significant increase in the time in
hypoglycaemia could be seen during CGM recording
days of Ramadan fasting. There is scarce data on the
rate of hypoglycaemia in non-insulin-treated patients
with type 2 diabetes during Ramadan fasting.
However, recent studies have shown that the newer
anti-diabetic medications – DPP-4 inhibitors, GLP-1
agonists, and SGLT2 inhibitors – are safe during
Ramadan fasting and have lower risk for hypoglycae-
mia compared to SU [12,14,18,19]. Pre-Ramadan indi-
vidualized advice and education provided at our
centre may have played a role in preventing signifi-
cant increase in the rate of hypoglycaemia [20,21].
Some limitations should be considered in the
present study. The patients who participated in
our study had non-insulin-treated well-controlled
diabetes and thus are not representative of all
patients with type 2 diabetes. This may, at least
partially, explain the lack of significant glucose
variability changes during Ramadan fasting.
Another consideration is the limited number of
patients participating in the study. Because the
early-Ramadan CGM recordings in our study were
done in the first 3 days of Ramadan, the initial
increased variability may be due to transition from
non-fasting normal daily life routines to different
daily routines with shift of mealtimes and altered
physical activity in this group of patients with well-
controlled diabetes. Another limitation to this study
is the low number of CGM recording days that may
reduce the possibility of exploring more glucose
fluctuation including hypoglycaemias during
Ramadan fasting period. More studies are needed
in patients with type 2 diabetes, both less well-
controlled and insulin-treated, to understand better
the effect of Ramadan fasting on glucose
fluctuation.
In conclusion, except for an initial increase in glu-
cose variability, fasting during Ramadan for patients
with non-insulin-treated type 2 diabetes did not cause
any significant changes in metabolic control, glucose
fluctuation, or time in hypoglycaemia during CGM
recording days compared to the non-fasting pre-
Ramadan period. Further pre- and early-Ramadan
patient education and follow-up of high-risk patients
may help avoid initial significant glucose variability in
patients with non-insulin-treated diabetes.
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MAGE All (n = 33) 54 (26–120) 70 (33–146) 0.007 67 (30–124) ns 65 (35–144) ns
















































CV 0.18 (0.12–0.41) 0.20 (0.10–0.34) ns 0.20 (0.13–0.30) ns 0.21 (0.12–0.28) ns
TIR (%) 92 (39–100) 93 (51–100) ns 92 (15–100) ns 91 (08–100) ns
TIHyper (%) 6 (0–61) 7 (0–49) ns 6 (0–85) ns 8 (0–92) ns
TIHypo (%) 0 (0–20) 0 (0–8) ns 0 (0–8) ns 0 (0–9) ns
Data are shown in median (range). P = P-value vs. pre-Ramadan. MAGE = mean amplitude of glucose excursions, ADM = anti-diabetic medication,
SU = sulphonylurea, CV = coefficient of variation, TIR = time in range (70–180 mg/dl), TIHyper = time in hyperglycemia.
(>180 mg/dl), TIHypo = time in hypoglycaemia (< 70mg/dl).
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